Siegler M - Search Results

1

Inside information: Financial conflicts of interest for research subjects in early phase clinical trials.

Helft PR, Ratain MJ, Epstein RA, Siegler M. Helft PR, et al. Among authors: siegler m. J Natl Cancer Inst. 2004 May 5;96(9):656-61. doi: 10.1093/jnci/djh121. J Natl Cancer Inst. 2004. PMID: 15126602 Review.

2

Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents.

Ratain MJ, Mick R, Schilsky RL, Siegler M. Ratain MJ, et al. Among authors: siegler m. J Natl Cancer Inst. 1993 Oct 20;85(20):1637-43. doi: 10.1093/jnci/85.20.1637. J Natl Cancer Inst. 1993. PMID: 8411243 Review. No abstract available.

3

Study of cohort-specific consent and patient control in phase I cancer trials.

Daugherty CK, Ratain MJ, Minami H, Banik DM, Vogelzang NJ, Stadler WM, Siegler M. Daugherty CK, et al. Among authors: siegler m. J Clin Oncol. 1998 Jul;16(7):2305-12. doi: 10.1200/JCO.1998.16.7.2305. J Clin Oncol. 1998. PMID: 9667244 Clinical Trial.

4

Ethical issues in phase I oncology research: a comparison of investigators and institutional review board chairpersons.

Kodish E, Stocking C, Ratain MJ, Kohrman A, Siegler M. Kodish E, et al. Among authors: siegler m. J Clin Oncol. 1992 Nov;10(11):1810-6. doi: 10.1200/JCO.1992.10.11.1810. J Clin Oncol. 1992. PMID: 1403062

5

Pushing the envelope: informed consent in phase I trials.

Daugherty CK, Ratain MJ, Siegler M. Daugherty CK, et al. Among authors: siegler m. Ann Oncol. 1995 Apr;6(4):321-3. doi: 10.1093/oxfordjournals.annonc.a059178. Ann Oncol. 1995. PMID: 7619746 Free article. No abstract available.

6

Learning from our patients: one participant's impact on clinical trial research and informed consent.

Daugherty CK, Siegler M, Ratain MJ, Zimmer G. Daugherty CK, et al. Among authors: siegler m. Ann Intern Med. 1997 Jun 1;126(11):892-7. doi: 10.7326/0003-4819-126-11-199706010-00008. Ann Intern Med. 1997. PMID: 9163291

7

Perceptions of cancer patients and their physicians involved in phase I trials.

Daugherty C, Ratain MJ, Grochowski E, Stocking C, Kodish E, Mick R, Siegler M. Daugherty C, et al. Among authors: siegler m. J Clin Oncol. 1995 May;13(5):1062-72. doi: 10.1200/JCO.1995.13.5.1062. J Clin Oncol. 1995. PMID: 7738612

8

Organizers' introduction to the Symposium on Quality Health Care.

Siegler M, Epstein RA. Siegler M, et al. Perspect Biol Med. 2003 Winter;46(1):1-4. doi: 10.1353/pbm.2003.0018. Perspect Biol Med. 2003. PMID: 12582264 No abstract available.

9

The rise and fall of the futility movement.

Helft PR, Siegler M, Lantos J. Helft PR, et al. Among authors: siegler m. N Engl J Med. 2000 Jul 27;343(4):293-6. doi: 10.1056/NEJM200007273430411. N Engl J Med. 2000. PMID: 10911014 No abstract available.

10

Patient-provider communications about pharmacogenomic results increase patient recall of medication changes.

Borden BA, Lee SM, Danahey K, Galecki P, Patrick-Miller L, Siegler M, Sorrentino MJ, Sacro Y, Davis AM, Rubin DT, Lipstreuer K, Polonsky TS, Nanda R, Harper WR, Koyner JL, Burnet DL, Stadler WM, Kavitt RT, Meltzer DO, Ratain MJ, O'Donnell PH. Borden BA, et al. Among authors: siegler m. Pharmacogenomics J. 2019 Dec;19(6):528-537. doi: 10.1038/s41397-019-0076-2. Epub 2019 Feb 4. Pharmacogenomics J. 2019. PMID: 30713337 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

551 results

Search Page